Sector News

How China is transforming the biotech industry: Brainstorm Health

October 8, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Fortune sat down with Brad Loncar, a biotech investor who specializes in cancer immunotherapy, at our offices last week. Loncar runs both a U.S.-based index fund for cancer drug companies and, more recently, launched another one focused on China.

It was a fascinating conversation that covered everything from the U.S. oncology field to the shifting global dynamics of cancer drug development.

It would be difficult to capture the entire conversation in a single missive. But I want to highlight one particularly interesting part—the evolving nature of China’s biotech industry, especially when it comes to the “biologic” drugs which have become a hotbed of cancer therapy innovation.

“The Chinese FDA is trying to replicate the U.S. FDA,” Loncar tells Fortune, noting that about half of the biggest, global biopharma IPOs last year occurred in China.

This presents a major shift for China. Brand name biologic drugs (the kind that are derived from biological, rather than chemical, material and are therefore much more difficult to produce) make up nearly 80% of the top-sellers in the U.S.; China, traditionally, has been much more focused on the generic market.

That’s changing. “They want to go from becoming just a manufacturer to a true innovator,” says Loncar.

The Chinese government is trying to make that happen through a series of policy shifts, including more stringent drug development standards in line with other nations (including the U.S.), new trade policies, and revamped stock market rules meant to fuel funds to early-stage drug companies.

Just how effective could these efforts prove? WuXi Biologics, a Chinese company whose technology platforms help produce a staggering 12% of the world’s biologic drugs, is aggressively expanding into American and European markets.

And here’s the kicker: Chinese companies could very well undercut American firms on pricing if their products pass muster and reach the U.S. market. If that’s really the wave of the future, U.S. drug makers are on notice.

By Sy Mukherjee

Source: Fortune

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 15, 2019

Merck builds in CNS diseases with $576m Calporta buy

Life sciences

LinkedIn Twitter FacebookMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 […]

November 14, 2019

Longtime Abbott chief Miles White, designer of AbbVie spinoff, bows out of CEO job

Life sciences

LinkedIn Twitter FacebookAbbott Laboratories chief Miles White will shed the CEO title next year after a 21-year run and several major transformations at the global healthcare company. White will officially […]

November 14, 2019

Thermo Fisher looks to buy fellow diagnostics maker Qiagen: Bloomberg

Life sciences

LinkedIn Twitter FacebookThermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, which has the potential to become one of its largest acquisitions, according to a […]

Subscribe to our Weekly Newsletter

We're easy to reach